In this episode, Dr. Dash, is joined by Dr. Rosa Coppolecchia, senior director of global clinical lead for thrombosis and vascular diseases at Bayer and assistant clinical professor of medicine at Hackensack Meridian School of Medicine. Dr. Coppolecchia shares her extensive 18-year experience in the pharmaceutical industry, focusing on cardiovascular and preventive medicine. They discuss her transition from practicing occupational medicine to joining Bayer in 2005, driven by personal experiences and a desire to impact cardiovascular health through research and clinical development. The conversation highlights her work on aspirin and other cardiovascular therapies, addressing health disparities, particularly among women, and the challenges and innovations in decentralized clinical trials. The discussion also touches on the evolution of cardiovascular disease treatment, the impact of new technologies like wearables and telemedicine, and the importance of patient education and compliance. Dr. Coppolecchia also shares her involvement in promoting STEM education among young women through the American Heart Association.

In this episode of Beyond the Chart, host Dr. Raj Dash interviews Priya Singh, Executive Vice President, Chief Strategy Officer, and Senior Associate Dean at Stanford Medicine. They discuss Priya's extensive career, her role in shaping Stanford Medicine's strategic initiatives, and the challenges of integrating diverse perspectives within a complex healthcare system. The conversation also covers the impact of emerging technologies like AI on healthcare and the importance of collaboration and alignment in achieving organizational success.

In this episode of Beyond the Chart, Dr. Dash welcomes Dr. Jo Anne Foody, \ Chief Medical Officer for Esperion Therapeutics. Dr. Foody is a renowned cardiologist with a prolific career spanning academia and industry. She transitioned from academic positions at Yale and Harvard Medical Schools to significant roles in the pharmaceutical industry, including Merck Research Labs and Johnson & Johnson.

Dr. Foody discusses her journey and achievements at Esperion, where she has been instrumental in the development of Bempedoic acid, an oral therapy for lowering cardiovascular risk. The conversation highlights the challenges and successes in conducting clinical trials, particularly the significant accomplishment of achieving gender parity in the CLEAR Outcomes study.

Dr. Foody emphasizes the importance of patient-centric approaches, real-world evidence, and the need for innovative risk models to improve preventive cardiology. She also touches on the necessity of addressing health disparities and the evolving landscape of cardiovascular therapies. The podcast concludes with a discussion on the future of drug development and the potential for precision medicine to transform patient care.